Supplementary Figure S3 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models

Authors :: Joaquim Bellmunt
Ana Rovira
Rachael Brake
Joan Albanell
Federico Rojo
Natalia Iarchouk
Alejandro Martínez
Luis Soria-Jiménez
Silvia Menéndez
Oriol Arpi
Nuria Juanpere-Rodero
Alejo Rodriguez-Vida
Anna Hernández-Prat
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: In vivo effects of TAK-228 on the T24 xenograft model.

Tools